Top

Published in:

01-11-2016 | Original Article

Creation of an apoptin-derived peptide that interacts with SH3 domains and inhibits glioma cell migration and invasion

Authors: Weiwei Song, Hengyu Zhao, Zhongqi Cui, Xiaoyu Ma, Wenwen Zhang, Di Wang, Anqi Liu, Lijie Yuan

Published in: Tumor Biology | Issue 11/2016

Abstract

Glioblastoma multiforme (GBM) is an aggressive tumor of the central nervous system characterized by high rates of recurrence, morbidity, and mortality. This study investigated the antitumor effects of an apoptin-derived peptide (ADP) on glioma cells and explored the underlying mechanisms. The U251, U87, and C6 glioma cell lines were used in the present study, and the expression of p-Akt, Akt, and MMP-9 was determined through Western blotting, quantitative real-time PCR, and hematoxylin and eosin (HE) staining. Tumor growth was evaluated by magnetic resonance imaging, and cell viability was assessed through an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MTT assay. Glioma cell metastasis was evaluated using transwell migration, invasion, and scratch-wound assays. An ADP was designed and synthesized based on the results of a domain-based analysis of the structure of apoptin. The ADP inhibited glioma cell viability, invasion and migration, and treatment with the synthesized ADP led to downregulation of p-Akt and MMP-9 and inhibited MMP-9 translation. The ADP also inhibited glioma invasion and migration in vivo, and HE staining showed decreases in the satellite-like invasion of cell masses and apoptotic cell populations after treatment with the ADP. Our findings demonstrate that treatment with an ADP can suppress glioma cell migration and invasion via the PI3K/Akt/MMP-9 signaling pathway and provide a new platform for the development of drugs for treating glioma.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. doi:10.1056/NEJMoa043330.CrossRefPubMed

Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006;5:637–44. doi:10.1158/1535-7163.MCT-05-0453.CrossRefPubMed

Griscelli F, Li H, Cheong C, Opolon P, Bennaceur-Griscelli A, Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci U S A. 2000;97:6698–703. doi:10.1073/pnas.110134297.CrossRefPubMedPubMedCentral

Backendorf C, Visser AE, de Boer AG, Zimmerman R, Visser M, Voskamp P, Zhang YH, Noteborn M. Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol. 2008;48:143–69. doi:10.1146/annurev.pharmtox.48.121806.154910.CrossRefPubMed

Kita D, Yonekawa Y, Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 2007;113:295–302. doi:10.1007/s00401-006-0186-1.CrossRefPubMed

Cámara-Artigas A, Martín-García JM, Morel B, Ruiz-Sanz J, Luque I. Intertwined dimeric structure for the SH3 domain of the c-Src tyrosine kinase induced by polyethylene glycol binding. FEBS Lett. 2009;583:749–53. doi:10.1016/j.febslet.2009.01.036.CrossRefPubMed

Noteborn MH, Koch G. Chicken anaemia virus infection: molecular basis of pathogenicity. Avian Pathol. 1995;24:11–31. doi:10.1080/03079459508419046.CrossRefPubMed

Singh PK, Tiwari AK, Rajmani RS, Kumar GR, Chaturvedi U, Saxena L, Saxena S, Doley J, Sahoo AP, Santra L, Saxena M, Kumar S, Sharma B. Apoptin as a potential viral gene oncotherapeutic agent. Appl Biochem Biotechnol. 2015;176:196–212. doi:10.1007/s12010-015-1567-5.CrossRefPubMed

Danen-Van Oorschot AAAM, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D, Noteborn MH. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem. 2003;278:27729–36.CrossRefPubMed

10.

Rollano Peñaloza OM, Lewandowska M, Stetefeld J, Ossysek K, Madej M, Bereta J, Sobczak M, Shojaei S, Ghavami S, Łos MJ. Apoptins: selective anticancer agents. Trends Mol Med. 2014;20:519–28. doi:10.1016/j.molmed.2014.07.003.CrossRefPubMed

11.

Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004;116:527–40. doi:10.1016/S0092-8674(04)00162-X.CrossRefPubMed

12.

Burek M, Maddika S, Burek CJ, Daniel PT, Schulze-Osthoff K, Los M. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene. 2006;25:2213–22. doi:10.1038/sj.onc.1209258.CrossRefPubMedPubMedCentral

13.

Yuan L, Zhao H, Zhang L, Liu X. The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma. Tumour Biol. 2013;34:3027–34. doi:10.1007/s13277-013-0867-z.CrossRefPubMed

14.

Yang X, Wang J, Zhou Y, Wang Y, Wang S, Zhang W. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett. 2012;321:137–43. doi:10.1016/j.canlet.2012.01.030.CrossRefPubMed

15.

Yuan L, Zhang L, Dong X, Zhao H, Li S, Han D, Liu X. Apoptin selectively induces the apoptosis of tumor cells by suppressing the transcription of HSP70. Tumour Biol. 2013;34:577–85. doi:10.1007/s13277-012-0585-y.CrossRefPubMed

16.

Poon IK, Oro C, Dias MM, Zhang J, Jans DA. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 2005;65:7059–64. doi:10.1158/0008-5472.CAN-05-1370.CrossRefPubMed

17.

Danen V, Oorschot AA, Zhang YH, Leliveld SR, Jennifer LR, Maud CMJS, Marian WB, Van Zon A, Stefan JE, Jan PA, Dominik M, Mathieu HMN. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem. 2003;13:27729–36.CrossRef

18.

Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann F, Schulze-Osthoff K. Apoptin, a tumor-selective killer. Biochim Biophys Acta. 2009;1793:1335–42. doi:10.1016/j.bbamcr.2009.04.002.CrossRefPubMed

19.

Rohn JL, Zhang YH, Aalbers RI, Otto N, Den Hertog J, Henriquez NV, van de Velde CJ, Kuppen PJ, Mumberg D, Donner P, Noteborn MH. A tumor-specific kinase activity regulates the viral death protein apoptin. J Biol Chem. 2002;277:50820–7. doi:10.1074/jbc.M208557200.CrossRefPubMed

20.

Lee YH, Cheng CM, Chang YF, Wang TY, Yuo CY. Apoptin T108 phosphorylation is not required for its tumor-specific nuclear localization but partially affects its apoptotic activity. Biochem Biophys Res Commun. 2007;354:391–5. doi:10.1016/j.bbrc.2006.12.201.CrossRefPubMed

21.

Leliveld SR, Dame RT, Mommaas MA, Koerten HK, Wyman C, Danen-van Oorschot AA, Rohn JL, Noteborn MH, Abrahams JP. Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA. Nucleic Acids Res. 2003;31:4805–13. doi:10.1093/nar/gkg661.CrossRefPubMedPubMedCentral

22.

Heilman DW, Teodoro JG, Green MR. Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J Virol. 2006;80:7535–45. doi:10.1128/JVI.02741-05.CrossRefPubMedPubMedCentral

23.

24.

Ma C, Li Y, Zhang X, Zhao G, Xu H. Levels of vascular endothelial growthfactor and matrix metalloproteinase-9 proteins in patients with glioma. J Int Med Res. 2014;42:198–204. doi:10.1177/0300060513481924.CrossRefPubMed

25.

Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol. 2012;2012:281261. doi:10.1155/2012/281261.CrossRefPubMed

26.

Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002;8:2894–901.PubMed

27.

Awasthi R, Pandey CM, Sahoo P, Behari S, Kumar V, Kumar S, Misra S, Husain N, Soni P, Rathore RK, Gupta RK. Dynamic contrast-enhanced magnetic resonance imaging-derived kep as a potential biomarker of matrix metalloproteinase 9 expression in patients with glioblastoma multiforme: a pilot study. J Comput Assist Tomogr. 2012;36:125–30. doi:10.1097/RCT.0b013e31823f6c59.CrossRefPubMed

28.

Zhao Y, Lyons Jr CE, Xiao A, Templeton DJ, Sang QA, Brew K, Hussaini IM. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochem Biophys Res Commun. 2008;369:1215–20. doi:10.1016/j.bbrc.2008.03.038.CrossRefPubMedPubMedCentral

Title: Creation of an apoptin-derived peptide that interacts with SH3 domains and inhibits glioma cell migration and invasion
Authors: Weiwei Song
Hengyu Zhao
Zhongqi Cui
Xiaoyu Ma
Wenwen Zhang
Di Wang
Anqi Liu
Lijie Yuan
Publication date: 01-11-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5404-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2016

Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study

Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway

The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo

IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway

MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma

Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer